Format

Send to

Choose Destination
J Affect Disord. 2019 Oct 1;257:17-22. doi: 10.1016/j.jad.2019.06.050. Epub 2019 Jul 2.

Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.

Author information

1
Mongan Institute Health Policy Center, Massachusetts General Hospital, Boston, MA, USA. Electronic address: vfung@mgh.harvard.edu.
2
Mongan Institute Health Policy Center, Massachusetts General Hospital, Boston, MA, USA.
3
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
4
Adult Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
5
Department of Psychiatry, University of Alabama, Birmingham, AL, USA.
6
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
7
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
8
Department of Psychiatry, Perelman School of Medicine, Philadelphia, PA, USA.
9
Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USA.

Abstract

BACKGROUND:

Complex polypharmacy (CP) is common in bipolar disorder (BD). We assessed the associations between CP, adherence, and side effect burden, and patient traits associated with clinical improvement in relationship to CP.

METHODS:

We conducted a secondary analysis of 482 adult BD participants in the Bipolar CHOICE trial. We examined the associations between CP (use of ≥3 BD medications) and non-adherence (missing >30% of BD medication doses in the last 30 days) and side effect burden (Frequency, Intensity and Burden of Side Effects Rating scale) using multivariate models with patient random effects. We used logistic regression to assess the patient traits associated with remission among those with majority CP use (Clinical Global Impression-Severity for BD score ≤2 for 8+ weeks).

RESULTS:

43% of patients had any CP and 25% had CP for the majority of the study. CP was associated with non-adherence (OR = 2.51, 95% CI [1.81, 3.50]), but not worse side effect burden. Among those with CP, 16% achieved remission; those with non-adherence, comorbid social or generalized anxiety disorder, or BD I vs. II were less likely to achieve remission among those with CP.

LIMITATIONS:

There could be unmeasured confounding between use of CP and side effect burden or adherence. Adherence was measured by self-report, which could be subject to reporting error.

CONCLUSIONS:

BD patients with CP were less likely to adhere to therapy, and those with worse adherence to CP were less likely to clinically respond. Clinicians should assess medication adherence prior to adding another agent to medication regimens.

KEYWORDS:

Bipolar disorder; Complex polypharmacy; Medication adherence; Polypharmacy

PMID:
31299400
PMCID:
PMC6711795
[Available on 2020-10-01]
DOI:
10.1016/j.jad.2019.06.050

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center